Literature DB >> 35100727

Evaluation of ALK Fusion Newly Identified in Colon Cancer by a Comprehensive Genomic Analysis.

Yasuyuki Hosono1, Toshiki Masuishi1, Seiichiro Mitani1, Rui Yamaguchi1,2, Seiichi Kato1, Takayuki Yoshino3, Hiromichi Ebi1,2.   

Abstract

Entities:  

Year:  2019        PMID： 35100727     DOI： 10.1200/PO.19.00268

Source DB:  PubMed          Journal:  JCO Precis Oncol        ISSN： 2473-4284


× No keyword cloud information.
  2 in total

1.  IKZF3 amplification frequently occurs in HER2-positive breast cancer and is a potential therapeutic target.

Authors:  Chih-Yi Lin; Chung-Jen Yu; Chia-I Shen; Chun-Yu Liu; Ta-Chung Chao; Chi-Cheng Huang; Ling-Ming Tseng; Jiun-I Lai
Journal:  Med Oncol       Date:  2022-09-30       Impact factor: 3.738

2.  SEOM-GECOD clinical guideline for unknown primary cancer (2021).

Authors:  Ferrán Losa; Isaura Fernández; Olatz Etxaniz; Alejandra Giménez; Paula Gomila; Lara Iglesias; Federico Longo; Esteban Nogales; Antonio Sánchez; Gemma Soler
Journal:  Clin Transl Oncol       Date:  2022-03-23       Impact factor: 3.405
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.